In The News

Genentech Fights For $5.8M In ‘Exceptional' IP Attys Fees


08 Mar 2018
Reprinted with permission.

Michael A. Jacobs, co-chair of Morrison & Foerster’s Intellectual Property Practice Group, believes that Phigenix’s suit against Genentech was baseless from the start based on the fact that Genentech had conducted clinical trials for its Kadcyla drug, and Phigenix should be required to pay the $5.8M in attorney fees that were requested. 

"That’s why we think there’s an original error here and we should go all the way back,” he said in the Law360 article “Genentech Fights For $5.8M In ‘Exceptional' IP Attys Fees.”





Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.